Efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes: a systematic review.

IF 1.4 4区医学 Q4 CELL BIOLOGY Cell and Tissue Banking Pub Date : 2024-06-01 Epub Date: 2024-02-21 DOI:10.1007/s10561-024-10128-1

Jiaxin Liu, Yang Yang, Yun Qi

{"title":"Efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes: a systematic review.","authors":"Jiaxin Liu, Yang Yang, Yun Qi","doi":"10.1007/s10561-024-10128-1","DOIUrl":null,"url":null,"abstract":"<p><p>To investigate the efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes. Articles about the effects of mesenchymal stromal cells for T1D were retrieved in PubMed, Web of Science, Embase, and the Cochrane Library databases up to July 2023. Additional relevant studies were manually searched through citations. HbA1c, FBG, PBG, insulin requirement and C-peptide were assessed. The risk of bias was evaluated with the ROB 2.0 and ROBINS-I tools. Six RCTs and eight nRCTs were included. Of the 14 studies included, two evaluated BM-MSCs, three evaluated UC-MSCs, five evaluated AHSCT, two evaluated CB-SCs, and two evaluated UC-SCs plus aBM-MNCs. At the end of follow-up, ten studies found that mesenchymal stromal cells improved glycemic outcomes in T1D, while the remaining four studies showed no significant improvement. Findings support the positive impacts observed from utilizing mesenchymal stromal cells in individuals with T1D. However, the overall methodological quality of the identified studies and findings is heterogeneous, limiting the interpretation of the therapeutic benefits of mesenchymal stromal cells in T1D. Methodically rigorous research is needed to further increase credibility.</p>","PeriodicalId":9723,"journal":{"name":"Cell and Tissue Banking","volume":" ","pages":"663-676"},"PeriodicalIF":1.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11143029/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell and Tissue Banking","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10561-024-10128-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To investigate the efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes. Articles about the effects of mesenchymal stromal cells for T1D were retrieved in PubMed, Web of Science, Embase, and the Cochrane Library databases up to July 2023. Additional relevant studies were manually searched through citations. HbA1c, FBG, PBG, insulin requirement and C-peptide were assessed. The risk of bias was evaluated with the ROB 2.0 and ROBINS-I tools. Six RCTs and eight nRCTs were included. Of the 14 studies included, two evaluated BM-MSCs, three evaluated UC-MSCs, five evaluated AHSCT, two evaluated CB-SCs, and two evaluated UC-SCs plus aBM-MNCs. At the end of follow-up, ten studies found that mesenchymal stromal cells improved glycemic outcomes in T1D, while the remaining four studies showed no significant improvement. Findings support the positive impacts observed from utilizing mesenchymal stromal cells in individuals with T1D. However, the overall methodological quality of the identified studies and findings is heterogeneous, limiting the interpretation of the therapeutic benefits of mesenchymal stromal cells in T1D. Methodically rigorous research is needed to further increase credibility.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

间充质基质细胞治疗 1 型糖尿病的疗效：系统综述。

研究间充质基质细胞治疗 1 型糖尿病的疗效。在PubMed、Web of Science、Embase和Cochrane图书馆数据库中检索了截至2023年7月有关间充质基质细胞治疗T1D效果的文章。此外，还通过引文手动搜索了其他相关研究。对 HbA1c、FBG、PBG、胰岛素需求量和 C 肽进行了评估。使用 ROB 2.0 和 ROBINS-I 工具评估了偏倚风险。共纳入六项研究性试验和八项非研究性试验。在纳入的 14 项研究中，2 项研究评估了 BM-间充质干细胞，3 项研究评估了 UC-间充质干细胞，5 项研究评估了 AHSCT，2 项研究评估了 CB-间充质干细胞，2 项研究评估了 UC-SC 加 aBM-MNC。在随访结束时，10 项研究发现间充质基质细胞改善了 T1D 患者的血糖结果，而其余 4 项研究则没有发现明显改善。研究结果支持利用间充质基质细胞对 T1D 患者产生的积极影响。然而，已确定的研究和发现的总体方法质量参差不齐，限制了对间充质基质细胞在 T1D 中治疗效果的解释。要进一步提高可信度，还需要进行方法严谨的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cell and Tissue Banking CELL BIOLOGY-ENGINEERING, BIOMEDICAL

CiteScore

3.10

自引率

13.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Cell and Tissue Banking provides a forum for disseminating information to scientists and clinicians involved in the banking and transplantation of cells and tissues. Cell and Tissue Banking is an international, peer-reviewed journal that publishes original papers in the following areas: basic research concerning general aspects of tissue banking such as quality assurance and control of banked cells/tissues, effects of preservation and sterilisation methods on cells/tissues, biotechnology, etc.; clinical applications of banked cells/tissues; standards of practice in procurement, processing, storage and distribution of cells/tissues; ethical issues; medico-legal issues.